Bilthoven Biologicals specializes in the development and production of vaccines, with a strong focus on the inactivated poliomyelitis vaccine (IPV). This vaccine is a crucial component of the Global Polio Eradication Programme, utilizing killed poliovirus to stimulate antibody production without causing disease. The company emphasizes high-quality manufacturing processes to ensure the reliability of its vaccines, contributing significantly to global vaccination efforts, including nearly half of the 60 million vaccinations administered annually by UNICEF.

In addition to IPV, Bilthoven Biologicals is involved in various collaborations aimed at advancing vaccine technology and production capabilities. Notably, the company has signed a technology transfer agreement with VACSERA in Egypt to facilitate local manufacturing of the injectable polio vaccine, marking a significant step towards self-sufficiency in vaccine production in the region. Furthermore, Bilthoven Biologicals is engaged in innovative projects, such as the development of a novel tuberculosis skin test and a viral vector-based vaccine for Mpox, showcasing its commitment to addressing public health challenges through advanced vaccine technologies.

Netherlands

Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 500 employees.

Bilthoven Biologicals

Company Details